肝内胆管癌的系统治疗
肝内胆管癌(iCCA)是一种高致死性肝胆肿瘤,发病率上升,常被误诊为原发不明癌。标准系统治疗包括一线吉西他滨联合顺铂、二线FOLFOX及辅助卡培他滨化疗。iCCA具有可靶向的FGFR2/NTRK融合及IDH1/BRAF突变,免疫治疗作用正在研究中。
要点
- 一线系统化疗为吉西他滨联合顺铂,二线为FOLFOX,辅助化疗为卡培他滨。
- iCCA存在可靶向的FGFR2和NTRK融合及IDH1和BRAF突变。
- 免疫治疗在iCCA中的作用正在积极研究中。
核心结论
- 肝内胆管癌系统治疗已有标准化疗方案,靶向治疗和免疫治疗是新兴方向。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- iCCA发病率上升,常被误诊为原发不明癌。
- 标准系统治疗包括一线吉西他滨联合顺铂、二线FOLFOX和辅助卡培他滨化疗。
- FGFR2和NTRK融合以及IDH1和BRAF可靶向突变已被全面表征,靶向这些驱动基因的临床数据正在涌现。
关键数值与推荐
- 一线系统化疗:吉西他滨联合顺铂;二线:FOLFOX;辅助化疗:卡培他滨。
- 可靶向遗传学改变包括FGFR2和NTRK融合、IDH1和BRAF突变。
临床怎么用
- 临床可依据标准方案进行系统化疗,并考虑对iCCA患者进行FGFR2、NTRK、IDH1和BRAF等靶点检测。
局限性
- 本文为综述,未报告系统检索策略及纳入研究的偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.
引用
- Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020. PMID: 31954497. doi:10.1016/j.jhep.2019.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。